

competition and will be returned to the applicant.

#### Where To Obtain Additional Information

To receive additional written information, call (404) 332-4561. You will be asked to leave your name, address, and telephone number. Please refer to Announcement #718. You will receive a complete program description, information on application procedures and application forms. If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from Gladys T. Gissentanna, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Mailstop E-18, Atlanta, GA 30305, telephone (404) 842-6801, fax (404) 842-6513. Programmatic technical assistance may be obtained from Kevin Brady, MPH, Assistant Branch Chief, Program Services Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE., Mailstop K-57, Atlanta, GA 30341-3724, telephone (404) 488-4343, fax (404) 488-4727. You may also obtain this announcement, and other CDC announcements, from one of two Internet sites on the actual publication date: CDC's homepage at <http://www.cdc.gov> or the Government Printing Office homepage (including free on-line access to the Federal Register at <http://www.access.gpo.gov>). Please refer to Announcement Number 718 when requesting information and submitting an application.

Potential applicants may obtain a copy of "Healthy People 2000" (Full Report, Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report, Stock No. 017-001-00473-1) referenced in the "Introduction" section through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: March 5, 1997.  
Joseph R. Carter,  
*Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).*  
[FR Doc. 97-5956 Filed 3-10-97; 8:45 am]  
BILLING CODE 4163-18-P

#### Current Status of the Vessel Sanitation Program and Experience to Date With Program Operations—Public Meeting

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

**Name:** Current Status of the Vessel Sanitation Program (VSP) and Experience to Date with Program Operations—Public meeting between CDC and the cruise ship industry, private sanitation consultants, and other interested parties.

**Time and Date:** 9 a.m.–12 noon, Thursday, April 3, 1997.

**Place:** Port of Miami, Terminal #10, Miami, Florida 33132. For directions call 305/536-4307, or fax 305/536-4528.

**Status:** Open to the public for participation, comment, and observation, limited only by the space available. The meeting room accommodates approximately 400 people.

**Purpose:** To discuss current status of the VSP and experience to date with program operations.

**Matters to be Discussed:** During the past 10 years, as part of the revised VSP, CDC has conducted a series of public meetings with members of the cruise ship industry, private sanitation consultants, and other interested parties. This meeting is a continuation of that series of public meetings. Some of the topics to be discussed at this meeting include the finalization of CDC's "Final Recommended Shipbuilding Construction Guidelines for Cruise Vessels Destined to Call on U.S. Ports," the finalization of "Interim Recommendations to Minimize Transmission of Legionnaires' Disease from Whirlpool Spas on Cruise Ships," revising the current VSP Operations Manual, status of development of a VSP

Hazard Analysis Critical Control Point training seminar and future plans for program direction.

For a period of 15 days following the meeting, through April 18, 1997, the official record of the meeting will remain open so that additional material or comments may be submitted to be made part of the record of the meeting.

Agenda items are subject to change as priorities dictate.

**Contact Person for More Information:** Dan Harper, Program Manager, VSP, Special Programs Group (F29), NCEH, CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30341-3724, telephone 770/488-3524.

Dated: March 5, 1997.  
Carolyn J. Russell  
*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC)*

[FR Doc. 97-5960 Filed 3-10-97; 8:45 am]  
BILLING CODE 4163-18-P

#### Administration for Children and Families

##### Submission for OMB Review; Comment Request

**Title:** Application Requirements or the Low Income Home Energy Assistance Program (LIHEAP) and Detailed Model Plan (submitted every 3 years. Abbreviated applications to be submitted in intervening years.)

**OMB No.:** 0970-0075.

**Description:** This information requirement is an annual activity which is required by law for the receipt of federal block grant funds under the LIHEAP statute. By law, we must make this model plan available to grantees. It provides grantees an optional management tool that may alleviate the burden of preparing additional information to complete plans. The detailed mode plan is to be filed only once every three years or sooner if major changes are made to grantee's program. We are also seeking approval for a streamlined application to be used in alternate years.

**Respondents:** State, Territories and Tribal Govts.

#### ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Detailed model plan .....	65	1	1	65
Abb. model plan .....	115	1	.33	38

Estimated Total Annual Burden Hours: 103.

**Additional Information:** Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Service, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

**OMB Comment:** OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: March 5, 1997.

Bob Sargis,

*Acting Reports Clearance Officer.*

[FR Doc. 97-6000 Filed 3-10-97; 8:45 am]

BILLING CODE 4184-01-M

## Food and Drug Administration

[Docket No. 93N-0190]

### Padam C. Bansal; Grant of Special Termination; Final Order Terminating Debarment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) granting special termination of the debarment of Dr. Padam C. Bansal, 9 Powelson Lane, Bridgewater, NJ 08807. FDA bases this order on a finding that Dr. Bansal has provided substantial assistance in the investigations or prosecutions of offenses relating to a matter under FDA's jurisdiction, and that special termination of Dr. Bansal's debarment serves the interest of justice and does not threaten the integrity of the drug approval process.

**EFFECTIVE DATE:** March 11, 1997.

**ADDRESSES:** Comments should reference Docket No. 93N-0190 and be sent to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Diane Sullivan-Ford, Center for Drug

Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** In the Federal Register of November 29, 1993 (58 FR 62674), Dr. Padam C. Bansal, the former Director of Research and Development at Par Pharmaceutical, Inc. (Par), was permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under sections 306(c)(1)(B), (c)(2)(A)(ii), and 201(dd) of the act (21 U.S.C. 335a(c)(1)(B), (c)(2)(A)(ii), and 321(dd)). The debarment was based on FDA's finding that Dr. Bansal was convicted of a felony under Federal law for conduct relating to the development or approval of any drug product, or otherwise relating to the regulation of a drug product (section 306(a)(2) of the act). On December 29, 1993, Dr. Bansal applied for special termination of debarment, under section 306(d)(4) of the act, as amended by the Generic Drug Enforcement Act.

Under section 306(d)(4)(C) and (D) of the act, FDA may limit the period of debarment of a permanently debarred individual if the agency finds that: (1) The debarred individual has provided substantial assistance in the investigation or prosecution of offenses described in subsections (a) or (b) of section 306 of the act or relating to a matter under FDA's jurisdiction; (2) termination of the debarment serves the interest of justice; and (3) termination of the debarment does not threaten the integrity of the drug approval process. Special termination of debarment is discretionary with FDA.

FDA considers a determination by the Department of Justice concerning the substantial assistance of a debarred individual conclusive in most cases. Dr. Bansal fully cooperated with the Department of Justice investigations and prosecutions of others within Par, as substantiated by two letters received by FDA from the Maryland U.S. Attorney's Office. Accordingly, FDA finds that Dr. Bansal provided substantial assistance as required by section 306(d)(4)(C) of the act.

The additional requisite showings, i.e., that termination of debarment serves the interest of justice and poses no threat to the integrity of the drug approval process, are difficult standards to satisfy. In determining whether these have been met, the agency weighs the significance of all favorable and unfavorable factors in light of the remedial, public health-related purposes underlying debarment. Termination of

debarment will not be granted unless, weighing all favorable and unfavorable information, there is a high level of assurance that the conduct that formed the basis for the debarment has not recurred and will not recur, and that the individual will not otherwise pose a threat to the integrity of the drug approval process.

Based on a thorough analysis of the available evidence, Dr. Padam C. Bansal has demonstrated that termination of his debarment serves the interest of justice and will not pose a threat to the integrity of the drug approval process.

Under section 306(d)(4)(D) of the act, the period of debarment of an individual who qualifies for special termination may be limited to less than permanent but to no less than 1 year. Dr. Bansal's period of debarment has lasted more than 1 year. Accordingly, the Deputy Commissioner for Operations, under section 306(d)(4) of the act and under authority delegated to him (21 CFR 5.20), finds that Dr. Padam C. Bansal's application for special termination of debarment should be granted, and that the period of debarment should terminate immediately, thereby allowing him to provide services in any capacity to a person with an approved or pending drug product application. The Deputy Commissioner for Operations further finds that because the agency is granting Dr. Bansal's application, an informal hearing under section 306(d)(4)(C) of the act is unnecessary.

As a result of the foregoing findings, Dr. Padam C. Bansal's debarment is terminated, effective (*insert date of publication in the Federal Register*) (section 306(d)(4)(C) and (D) of the act).

Dated: February 27, 1997.

Michael A. Friedman,

*Deputy Commissioner for Operations.*

[FR Doc. 97-5964 Filed 3-10-97; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 93N-0252]

### Atul Shah; Grant of Special Termination; Final Order Terminating Debarment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is issuing a final order under the Federal Food, Drug, and Cosmetic Act (the act) granting special termination of the debarment of Dr. Atul Shah, 20 Hampton Hollow Dr., Perrineville, NJ 08535. FDA bases this order on a finding that Dr. Shah has